CervoMed Advances Neflamapimod With Phase 1 Completion

The latest update is out from CervoMed ( (CRVO) ).

On March 4, 2026, CervoMed reported completion of a Phase 1 healthy volunteer study assessing the pharmacokinetics of a new, stable crystal form of its lead drug neflamapimod, manufactured via a controlled process to avoid prior polymorph-related variability. The company said the new formulation’s bioavailability and pharmacokinetic profile largely overlap with the clinically active drug product used in the extension phase of the Phase 2b RewinD-LB trial.

Based on these data, CervoMed has selected a 50mg three-times-daily dosing regimen of the stable crystal form of neflamapimod for its planned Phase 3 dementia with Lewy bodies trial, aiming to match plasma drug levels associated with prior clinical and biomarker benefits. Management highlighted that resolving historical manufacturing and bioavailability issues is intended to position the Phase 3 program to reproduce the positive outcomes seen with the effective batch in RewinD-LB, a key step for the company’s late-stage development strategy in neurodegenerative disease.

The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

The score is held down primarily by weak financial performance—large and widening losses with accelerating cash burn and a shrinking equity base. Technicals also remain bearish with the stock below major moving averages and negative momentum. Offsetting these risks, recent FDA alignment and Phase 2b data provide positive clinical/regulatory catalysts, but valuation signals are limited due to negative earnings and no dividend.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. Its lead oral small-molecule candidate, neflamapimod, targets neuroinflammation and neurodegeneration and is being developed for dementia with Lewy bodies, recovery after ischemic stroke, and primary progressive aphasia.

Neflamapimod has shown signals of efficacy and good tolerability in multiple Phase 1 and 2 trials, including AscenD-LB and RewinD-LB, particularly in dementia with Lewy bodies patients without Alzheimer’s co-pathology. The company aims to advance neflamapimod into a global pivotal Phase 3 program in dementia with Lewy bodies, contingent on securing sufficient funding.

Average Trading Volume: 75,611

Technical Sentiment Signal: Sell

Current Market Cap: $37.1M

See more data about CRVO stock on TipRanks’ Stock Analysis page.